Plain-English translation of NCT04477343 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new drug called combined with nivolumab, an immunotherapy medication, in people with advanced pancreatic cancer who have already completed at least 16 weeks of initial chemotherapy. The study wants to find the right dose of this medication and understand how it works in the body. Researchers are also looking at how the treatment changes the cancer's environment at the microscopic level.
Pancreatic cancer is very difficult to treat, and most patients need new treatment options after their first round of chemotherapy. This medication is being tested to see if it can help the immune system work better against the cancer and prevent it from growing.
You would take an oral pill of the medication twice daily at home, and receive an intravenous infusion of nivolumab every two weeks at a clinic. The study includes regular doctor visits, blood tests, and two biopsies (samples of your tumor) to see how the treatment is working and affecting your cancer. The trial is enrolling about 20 people total and is currently open but not accepting new participants at this moment.
AI-generated summary from trial data · Jul 12, 2026 · Not medical advice
United States